The 2th edition of the Highly Potent APIs Summit in Prague will bring together professionals that will present and share their experience on handling highly potent compounds with focus on early process development and scale up, occupational health regulations and safety standards, and more.
For detailed information, visit www.qepler.com
Meet Maurits Janssen, Ph.D, Senior Director & Head of Commercial Development API for Lonza Pharma & Biotech and one of our Subject Matter Experts for Highly Potent APIs & ADCs
Wednesday, 19 February 2020 at 11.10 am
Novotel Praha Hotel
Learn about Lonza best practices for development and manufacturing that facilitate accelerated timelines for highly potent APIs and ADCs.
APIs and Toxins/Linkers for ADCs:
A Vision on Highly Potent Development, Scale-up and Manufacturing.
Drug product development based on potent compounds can be quite challenging. Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost. These hurdles can be further challenging when the potent compound is used as toxin/linker for application in ADCs.
Leveraging established best practices and expertise can benefit your HPAPI and ADC drug programs and result in accelerated development and commercialization:
Can’t attend the show? Access our recent webinar HPAPIs and ADCs – a journey through high potency by clicking here
Use the form below to schedule a meeting with Lonza during Highly Potent APIs Summit.